Sweden

Spago Nanomedical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Spago Nanomedical Appoints Candidate Drug in the Tumorad Project

Lead Product(s): Tumorad-Lu177

Therapeutic Area: Oncology Product Name: SN201

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 24, 2020

Details:

In a mouse model for breast cancer, Spago has shown that Tumorad® significantly reduces tumor growth and prolongs survival. Based on this and previously communicated progress in the project, Spago has nominated Tumorad® or SN201 for Pre-clinical safety tests.

BioInvent

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

BioInvent and Transgene's BT-001 Achieves Outstanding Tumor Cure Rates in Preclinical Models

Lead Product(s): BT-001

Therapeutic Area: Oncology Product Name: BT-001

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Transgene

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 22, 2020

Details:

Cure rates exceeding 70% were seen in multiple mouse models, demonstrating the powerful therapeutic effect of BT-001 when used as a single agent, providing a solid basis for BT-001’s upcoming clinical development, with a phase I clinical trial expected to start in 2020.

Alligator Bioscience

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Aptevo Therapeutics and Alligator Bioscience Present new Preclinical Data for ALG.APV-527 at the PEGS Virtual Interactive Global Summit

Lead Product(s): ALG.APV-527

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 10, 2020

Details:

The preclinical data presented at the PEGS Global Summit show that ALG.APV-527 may overcome many of the limitations of competitor 4-1BB antibodies as it selectively enhances the function of activated T cells and NK cells in the presence of the tumor antigen 5T4.

BioInvent

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

BioInvent Expands Anti-TNFR2 Program by Selecting Second Monoclonal Antibody for Further Development

Lead Product(s): BI-1808

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 15, 2020

Details:

AACR abstract outlines two monoclonal antibodies selected for further development, BI-1808 and BI-1910, both generated using our proprietary n-CoDeR® library and F.I.R.S.TTM technology.

Sprint Bioscience

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Sprint Bioscience Publishes Scientific Study With New Positive Data from the Vps34 Program

Lead Product(s): SB02024

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 30, 2020

Details:

The research results show that SB02024 activates the immune system in tumors in malignant melanoma and colorectal cancer.

Lidds

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

LIDDS announces positive preclinical data for NanoZolid®-TLR9 agonist project

Lead Product(s): NZ-TLR9

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 25, 2020

Details:

Clinical data have shown that intratumoral delivery of TLR9 agonists can effectively treat solid cancers.

Active Biotech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Active Biotech announces new direction

Lead Product(s): Tasquinimod

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 05, 2020

Details:

Tasquinimod will be advanced in a new academic partnership, as an immunomodulatory product with a novel mechanism of action, for the treatment of multiple myeloma.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Spago Nanomedical

Spago Nanomedical Appoints Candidate Drug in the Tumorad Project

BioInvent

BioInvent and Transgene's BT-001 Achieves Outstanding Tumor Cure Rates in Preclinical Models

Alligator Bioscience

Aptevo Therapeutics and Alligator Bioscience Present new Preclinical Data for ALG.APV-527 at the PEGS Virtual Interactive Global Summit

BioInvent

BioInvent Expands Anti-TNFR2 Program by Selecting Second Monoclonal Antibody for Further Development

Sprint Bioscience

Sprint Bioscience Publishes Scientific Study With New Positive Data from the Vps34 Program

Lidds

LIDDS announces positive preclinical data for NanoZolid®-TLR9 agonist project

Active Biotech

Active Biotech announces new direction